Researchers have identified a type of pro-fibrotic immune cell associated with pulmonary fibrosis (PF) in people who develop persistent…
Articles by Steve Bryson, PhD
Enrollment has been completed for a Phase 2a study that’s testing idiopathic pulmonary fibrosis (IPF) treatment BBT-877, an investigational therapy…
Pliant Therapeutics’ bexotegrast reversed the signs of lung scarring, while improving lung function and easing cough severity in people…
Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary…
Pliant Therapeutics’ Phase 2b BEACON-IPF trial testing bexotegrast, an investigational oral treatment, in people with idiopathic pulmonary fibrosis…
GRI Bio has been given the green light to begin a Phase 2a clinical trial testing its lead program candidate…
Adults with idiopathic pulmonary fibrosis (IPF) who had greater diversity of mouth bacteria tended to have worse lung function…
Berberine, a naturally occurring plant compound, eased the signs and symptoms of pulmonary fibrosis (PF) in a mouse…
Use of cancer chemotherapy agents or rituximab to treat autoimmune diseases was associated with an increased risk of pulmonary…
The experimental oral therapy BMS-986278, taken at 60 mg twice daily for 26 weeks, resulted in a 69% reduction in…